KR100595459B1 - 비만 억제용 조성물 - Google Patents
비만 억제용 조성물 Download PDFInfo
- Publication number
- KR100595459B1 KR100595459B1 KR1020040038483A KR20040038483A KR100595459B1 KR 100595459 B1 KR100595459 B1 KR 100595459B1 KR 1020040038483 A KR1020040038483 A KR 1020040038483A KR 20040038483 A KR20040038483 A KR 20040038483A KR 100595459 B1 KR100595459 B1 KR 100595459B1
- Authority
- KR
- South Korea
- Prior art keywords
- obesity
- group
- present
- bark extract
- lacquer
- Prior art date
Links
- 208000008589 Obesity Diseases 0.000 title claims abstract description 52
- 235000020824 obesity Nutrition 0.000 title claims abstract description 52
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 18
- 239000000203 mixture Substances 0.000 title claims abstract description 17
- 239000004480 active ingredient Substances 0.000 claims abstract description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 238000000605 extraction Methods 0.000 claims description 3
- 239000012046 mixed solvent Substances 0.000 claims description 2
- 239000004922 lacquer Substances 0.000 abstract description 30
- 235000009200 high fat diet Nutrition 0.000 abstract description 25
- 210000000577 adipose tissue Anatomy 0.000 abstract description 13
- 239000003814 drug Substances 0.000 abstract description 10
- 238000010171 animal model Methods 0.000 abstract description 9
- 210000003743 erythrocyte Anatomy 0.000 abstract description 9
- 150000003626 triacylglycerols Chemical class 0.000 abstract description 9
- 210000000265 leukocyte Anatomy 0.000 abstract description 8
- 102000001554 Hemoglobins Human genes 0.000 abstract description 7
- 108010054147 Hemoglobins Proteins 0.000 abstract description 7
- 238000005534 hematocrit Methods 0.000 abstract description 7
- 201000010063 epididymitis Diseases 0.000 abstract description 6
- 210000004185 liver Anatomy 0.000 abstract description 5
- 210000004698 lymphocyte Anatomy 0.000 abstract description 5
- 210000001616 monocyte Anatomy 0.000 abstract description 5
- 230000002489 hematologic effect Effects 0.000 abstract description 4
- 235000005911 diet Nutrition 0.000 description 18
- 239000013641 positive control Substances 0.000 description 17
- 230000037213 diet Effects 0.000 description 16
- 230000000694 effects Effects 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 238000000034 method Methods 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 241000208225 Rhus Species 0.000 description 7
- 235000014220 Rhus chinensis Nutrition 0.000 description 7
- 239000002504 physiological saline solution Substances 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 244000044283 Toxicodendron succedaneum Species 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 235000021050 feed intake Nutrition 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 230000004584 weight gain Effects 0.000 description 4
- 235000019786 weight gain Nutrition 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000009207 exercise therapy Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 235000021590 normal diet Nutrition 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- 235000003840 Amygdalus nana Nutrition 0.000 description 2
- 244000296825 Amygdalus nana Species 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010033307 Overweight Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 235000011432 Prunus Nutrition 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000000883 anti-obesity agent Substances 0.000 description 2
- 238000013542 behavioral therapy Methods 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 235000005686 eating Nutrition 0.000 description 2
- 238000005265 energy consumption Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 229940041476 lactose 100 mg Drugs 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000037323 metabolic rate Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 206010033675 panniculitis Diseases 0.000 description 2
- 235000014774 prunus Nutrition 0.000 description 2
- 238000001671 psychotherapy Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000009182 swimming Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- RMTXUPIIESNLPW-UHFFFAOYSA-N 1,2-dihydroxy-3-(pentadeca-8,11-dienyl)benzene Natural products CCCC=CCC=CCCCCCCCC1=CC=CC(O)=C1O RMTXUPIIESNLPW-UHFFFAOYSA-N 0.000 description 1
- QARRXYBJLBIVAK-UEMSJJPVSA-N 3-[(8e,11e)-pentadeca-8,11-dienyl]benzene-1,2-diol;3-[(8e,11e)-pentadeca-8,11,14-trienyl]benzene-1,2-diol;3-[(8e,11e,13e)-pentadeca-8,11,13-trienyl]benzene-1,2-diol;3-[(e)-pentadec-8-enyl]benzene-1,2-diol;3-pentadecylbenzene-1,2-diol Chemical compound CCCCCCCCCCCCCCCC1=CC=CC(O)=C1O.CCCCCC\C=C\CCCCCCCC1=CC=CC(O)=C1O.CCC\C=C\C\C=C\CCCCCCCC1=CC=CC(O)=C1O.C\C=C\C=C\C\C=C\CCCCCCCC1=CC=CC(O)=C1O.OC1=CC=CC(CCCCCCC\C=C\C\C=C\CC=C)=C1O QARRXYBJLBIVAK-UEMSJJPVSA-N 0.000 description 1
- IYROWZYPEIMDDN-UHFFFAOYSA-N 3-n-pentadec-8,11,13-trienyl catechol Natural products CC=CC=CCC=CCCCCCCCC1=CC=CC(O)=C1O IYROWZYPEIMDDN-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 241000208223 Anacardiaceae Species 0.000 description 1
- 241001465677 Ancylostomatoidea Species 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000034577 Benign intracranial hypertension Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000018127 Idiopathic intracranial hypertension Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000013367 dietary fats Nutrition 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000002366 lipolytic effect Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 235000020830 overeating Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 238000010149 post-hoc-test Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 208000001381 pseudotumor cerebri Diseases 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- DQTMTQZSOJMZSF-UHFFFAOYSA-N urushiol Natural products CCCCCCCCCCCCCCCC1=CC=CC(O)=C1O DQTMTQZSOJMZSF-UHFFFAOYSA-N 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 229940002552 xenical Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/22—Anacardiaceae (Sumac family), e.g. smoketree, sumac or poison oak
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/3262—Foods, ingredients or supplements having a functional effect on health having an effect on blood cholesterol
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Botany (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
실험군 | 사료 섭취량(g/day) | 체중 증가(g/mice) | 사료 효율(%) |
N+S | 2.67±0.23a | 0.06±0.03a | 2.15±1.19a |
HF+S | 2.03±0.09b | 0.11±0.03a | 5.37±1.63b |
HF+X | 2.0±0.11b | 0.09±0.03ab | 4.37±1.68b |
HF+RVS | 1.96±0.04b | 0.09±0.03ab | 4.43±1.43b |
실험군 | 간(g) | 부고환 피하 지방조직(g) | 신장후 복막하 지방조직(g) |
N+S | 0.79±0.04 | 0.37±0.08a | 0.11±0.04a |
HF+S | 0.76±0.04 | 0.97±0.25b | 0.33±0.08b |
HF+X | 0.78±0.65 | 0.93±0.25b | 0.33±0.08b |
HF+RVS | 0.75±0.05 | 0.83±0.20b | 0.30±0.12b |
실험군 | 백혈구수 (WBC) (×103/㎖) | 림프구 백분율 (LY)(%) | 다핵구 백분율 (GR)(%) | 단핵구 백분율 (MO)(%) | 적혈구수 (RBC) (×106/㎖) | 헤모글로빈 농도(HB) (g/㎗) | 헤마토크리트 (Hct)(%) | 혈소판수(PLT) (×106/㎖) |
N+S | 2.37± 0.36a | 81.57±4.86 | 13.13±5.10 | 5.28± 1.10a | 9.37± 0.19a | 14.35±0.38ac | 46.18± 1.57a | 121.77±12.36a |
HF+S | 2.82± 0.76a | 82.75±6.18 | 11.15±4.60 | 5.78± 2.22a | 9.27± 0.18ab | 14.17±0.23ab | 46.28± 1.28a | 108.11±14.12b |
HF+X | 2.94± 0.30a | 84.80±2.49 | 8.96± 2.67 | 6.24± 1.36a | 9.11± 0.2b | 14.04±0.39b | 46.59± 1.62a | 124.10±13.31a |
HF+RVS | 3.20± 0.82b | 81.67±6.08 | 11.45±5.48 | 6.88± 1.50b | 9.58± 0.12c | 14.57±0.15c | 48.75± 1.55b | 122.60±22.93a |
실험군 | GOT (IU/ℓ) | GPT (IU/ℓ) | 콜레스테롤 (㎎/㎗) | 혈당치 (㎎/㎗) | 트리글리세라이드 (㎎/㎗) |
N+S | 118.0±58.28 | 32.55±6.18 | 82.40±7.66a | 69.8±25.39a | 38.9±16.87a |
HF+S | 125.88±48.60 | 29.22±8.74 | 88.88±9.22a | 81.55±50.08ab | 55.9±34.92a |
HF+X | 128.9±42.21 | 31.55±9.48 | 110.0±11.13b | 106.60±39.02b | 71.5±18.48b |
HF+RVS | 166.7±41.69 | 36.4±19.60 | 100.4±14.15b | 69.1±27.47a | 41.0±8.41ac |
Claims (3)
- 옻나무 껍질 추출물을 유효성분으로 하는 비만 억제용 조성물.
- 제 1항에 있어서, 상기 옻나무 껍질 추출물은 물, 알콜 또는 물과 알콜의 혼합용매로 추출하여 얻은 것임을 특징으로 하는 비만 억제용 조성물.
- 제 2항에 있어서, 상기 알콜은 메탄올인 것을 특징으로 하는 비만 억제용 조성물.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020040038483A KR100595459B1 (ko) | 2004-05-28 | 2004-05-28 | 비만 억제용 조성물 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020040038483A KR100595459B1 (ko) | 2004-05-28 | 2004-05-28 | 비만 억제용 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20050113003A KR20050113003A (ko) | 2005-12-01 |
KR100595459B1 true KR100595459B1 (ko) | 2006-07-03 |
Family
ID=37287790
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020040038483A KR100595459B1 (ko) | 2004-05-28 | 2004-05-28 | 비만 억제용 조성물 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100595459B1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105056117A (zh) * | 2015-08-05 | 2015-11-18 | 成都市飞龙水处理技术研究所 | 一种治疗副睾肿大的汤剂药物及其制备方法 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100710657B1 (ko) * | 2005-11-24 | 2007-04-24 | 코스맥스 주식회사 | 디하이드로퀘세틴을 함유하는 미백 화장료 조성물 |
KR102203550B1 (ko) * | 2018-11-23 | 2021-01-18 | (주)헬스코치생명공학 | Atdiet-801을 포함하는 당뇨병 및 비만 개선, 예방 또는 치료용 조성물 |
KR102178199B1 (ko) * | 2019-02-13 | 2020-11-13 | 재단법인 임실치즈앤식품연구소 | 옻나무 및 두충으로 구성된 조합 추출물을 유효성분으로 함유하는 비만증의 예방 및 치료용 조성물 |
KR102197352B1 (ko) * | 2019-08-30 | 2021-01-04 | 키븐 푸즈 아이엔씨. | 우루시올 함량 저감 조성물의 제조 방법, 그 제조 방법에 의하여 제조되는 조성물, 비만 방지제, 지방 축적 억제제 및 혈중 렙틴양 증가 억제제 |
-
2004
- 2004-05-28 KR KR1020040038483A patent/KR100595459B1/ko active IP Right Grant
Non-Patent Citations (1)
Title |
---|
한국생명과학회지 10(5), 467-474, 2000 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105056117A (zh) * | 2015-08-05 | 2015-11-18 | 成都市飞龙水处理技术研究所 | 一种治疗副睾肿大的汤剂药物及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
KR20050113003A (ko) | 2005-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100645385B1 (ko) | 비만 억제용 조성물 | |
JP2009511468A5 (ko) | ||
CN102885306A (zh) | 一种辅助降血脂的保健食品组合物及其制备方法 | |
JP2011522844A (ja) | 血糖レベルを低下させる組成物及びその用途 | |
JP4921681B2 (ja) | 予防薬剤 | |
KR100595459B1 (ko) | 비만 억제용 조성물 | |
EP3403664B1 (en) | Use of cistanche tubulosa | |
JP2007269631A (ja) | 中性脂肪蓄積抑制剤 | |
KR20110105627A (ko) | 누에 체액을 함유하는 항비만 조성물 | |
KR20120010464A (ko) | 생약 추출물을 유효성분으로 포함하는 숙취 해소용 조성물 및 그의 제조 방법 | |
KR20090087671A (ko) | 두충을 이용한 고혈압 억제 음료 개발 | |
KR20100088794A (ko) | 새송이버섯 추출물을 유효성분으로 함유하는 제 2형 당뇨병에 의한 지질대사 장애 및 당뇨합병증 질환의 예방 및 치료용 조성물 | |
KR101113603B1 (ko) | 간기능 개선 및 숙취해소 증진 기능을 가지는 한방복합제재 조성물(dts20, dts21) 및 그의 제조방법 | |
KR100679290B1 (ko) | Hgdsj201 생약 복합제 추출물을 포함하는 비만의예방 및 치료용 조성물 | |
JP2006182706A (ja) | 血中アディポネクチン量増加剤 | |
KR100293890B1 (ko) | 동아녹즙및그잔사를사용하여제조된체중및혈당조절용식품조성물및그제조방법 | |
KR100940133B1 (ko) | 지각 추출물을 함유하는 당뇨병 치료 조성물 및 이를유효성분으로 하는 건강보조식품 | |
KR101688126B1 (ko) | 고지혈증 또는 비만의 예방 또는 치료용 약제학적 조성물 및 이의 제조 방법 | |
KR101451809B1 (ko) | 율무 및 꾸지뽕잎을 유효성분으로 포함하는 대사질환의 예방, 치료 또는 개선용 조성물 | |
KR100573592B1 (ko) | 비만치료·억제용 백모근 추출물 | |
KR100758364B1 (ko) | 발기부전 예방 또는 치료용 약학 조성물 | |
KR100573590B1 (ko) | 비만치료ㆍ억제용 생약 조성물 | |
KR100761938B1 (ko) | 고지혈증 및/또는 고혈압에 기인한 발기부전 예방 또는치료용 약학 조성물 | |
KR100573591B1 (ko) | 비만치료ㆍ억제용 맥문동 추출물 | |
CN113181173A (zh) | 药用组合物及其在制备用于预防和/或治疗肝癌的产品中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20120626 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20120824 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20150316 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20160622 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20170412 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20180827 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20190403 Year of fee payment: 14 |